Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1983 2
1986 1
2003 1
2012 1
2013 1
2017 1
2018 2
2019 2
2020 10
2021 8
2022 9
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
High-Throughput Screening for Drug Combinations.
Shinn P, Chen L, Ferrer M, Itkin Z, Klumpp-Thomas C, McKnight C, Michael S, Mierzwa T, Thomas C, Wilson K, Guha R. Shinn P, et al. Among authors: itkin z. Methods Mol Biol. 2019;1939:11-35. doi: 10.1007/978-1-4939-9089-4_2. Methods Mol Biol. 2019. PMID: 30848454
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Thomas A, Takahashi N, Rajapakse VN, Zhang X, Sun Y, Ceribelli M, Wilson KM, Zhang Y, Beck E, Sciuto L, Nichols S, Elenbaas B, Puc J, Dahmen H, Zimmermann A, Varonin J, Schultz CW, Kim S, Shimellis H, Desai P, Klumpp-Thomas C, Chen L, Travers J, McKnight C, Michael S, Itkin Z, Lee S, Yuno A, Lee MJ, Redon CE, Kindrick JD, Peer CJ, Wei JS, Aladjem MI, Figg WD, Steinberg SM, Trepel JB, Zenke FT, Pommier Y, Khan J, Thomas CJ. Thomas A, et al. Among authors: itkin z. Cancer Cell. 2021 Apr 12;39(4):566-579.e7. doi: 10.1016/j.ccell.2021.02.014. Cancer Cell. 2021. PMID: 33848478 Free PMC article.
A landscape of response to drug combinations in non-small cell lung cancer.
Nair NU, Greninger P, Zhang X, Friedman AA, Amzallag A, Cortez E, Sahu AD, Lee JS, Dastur A, Egan RK, Murchie E, Ceribelli M, Crowther GS, Beck E, McClanaghan J, Klump-Thomas C, Boisvert JL, Damon LJ, Wilson KM, Ho J, Tam A, McKnight C, Michael S, Itkin Z, Garnett MJ, Engelman JA, Haber DA, Thomas CJ, Ruppin E, Benes CH. Nair NU, et al. Among authors: itkin z. Nat Commun. 2023 Jun 28;14(1):3830. doi: 10.1038/s41467-023-39528-9. Nat Commun. 2023. PMID: 37380628 Free PMC article.
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
Lang M, Schmidt LS, Wilson KM, Ricketts CJ, Sourbier C, Vocke CD, Wei D, Crooks DR, Yang Y, Gibbs BK, Zhang X, Klumpp-Thomas C, Chen L, Guha R, Ferrer M, McKnight C, Itkin Z, Wangsa D, Wangsa D, James A, Difilippantonio S, Karim B, Morís F, Ried T, Merino MJ, Srinivasan R, Thomas CJ, Linehan WM. Lang M, et al. Among authors: itkin z. J Exp Clin Cancer Res. 2023 Apr 25;42(1):99. doi: 10.1186/s13046-023-02667-4. J Exp Clin Cancer Res. 2023. PMID: 37095531 Free PMC article.
Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex.
Sun Y, Baechler SA, Zhang X, Kumar S, Factor VM, Arakawa Y, Chau CH, Okamoto K, Parikh A, Walker B, Su YP, Chen J, Ting T, Huang SN, Beck E, Itkin Z, McKnight C, Xie C, Roper N, Nijhawan D, Figg WD, Meltzer PS, Yang JC, Thomas CJ, Pommier Y. Sun Y, et al. Among authors: itkin z. Nat Commun. 2023 Jun 23;14(1):3762. doi: 10.1038/s41467-023-39374-9. Nat Commun. 2023. PMID: 37353483 Free PMC article.
High-throughput approaches to uncover synergistic drug combinations in leukemia.
Chory EJ, Wang M, Ceribelli M, Michalowska AM, Golas S, Beck E, Klumpp-Thomas C, Chen L, McKnight C, Itkin Z, Wilson KM, Holland D, Divakaran S, Bradner J, Khan J, Gryder BE, Thomas CJ, Stanton BZ. Chory EJ, et al. Among authors: itkin z. SLAS Discov. 2023 Jun;28(4):193-201. doi: 10.1016/j.slasd.2023.04.004. Epub 2023 Apr 29. SLAS Discov. 2023. PMID: 37121274 Free article.
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
Wu JT, Cheuk A, Isanogle K, Robinson C, Zhang X, Ceribelli M, Beck E, Shinn P, Klumpp-Thomas C, Wilson KM, McKnight C, Itkin Z, Sotome H, Hirai H, Calleja E, Wacheck V, Gouker B, Peer CJ, Corvalan N, Milewski D, Kim YY, Figg WD, Edmondson EF, Thomas CJ, Difilippantonio S, Wei JS, Khan J. Wu JT, et al. Among authors: itkin z. Cancers (Basel). 2023 Aug 9;15(16):4034. doi: 10.3390/cancers15164034. Cancers (Basel). 2023. PMID: 37627061 Free PMC article.
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.
Peat TJ, Gaikwad SM, Dubois W, Gyabaah-Kessie N, Zhang S, Gorjifard S, Phyo Z, Andres M, Hughitt VK, Simpson RM, Miller MA, Girvin AT, Taylor A, Williams D, D'Antonio N, Zhang Y, Rajagopalan A, Flietner E, Wilson K, Zhang X, Shinn P, Klumpp-Thomas C, McKnight C, Itkin Z, Chen L, Kazandijian D, Zhang J, Michalowski AM, Simmons JK, Keats J, Thomas CJ, Mock BA. Peat TJ, et al. Among authors: itkin z. Cancer Lett. 2023 Aug 1;568:216284. doi: 10.1016/j.canlet.2023.216284. Epub 2023 Jun 24. Cancer Lett. 2023. PMID: 37356470
Synergistic and Antagonistic Drug Combinations against SARS-CoV-2.
Bobrowski T, Chen L, Eastman RT, Itkin Z, Shinn P, Chen CZ, Guo H, Zheng W, Michael S, Simeonov A, Hall MD, Zakharov AV, Muratov EN. Bobrowski T, et al. Among authors: itkin z. Mol Ther. 2021 Feb 3;29(2):873-885. doi: 10.1016/j.ymthe.2020.12.016. Epub 2020 Dec 15. Mol Ther. 2021. PMID: 33333292 Free PMC article.
42 results